Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors


In 2017, an estimated 558 000 new cases of drug-resistant tuberculosis (TB) were diagnosed; most of these (82 %) were multidrug-resistant (MDR), meaning they are resistant to at least two of the most effective, front line antibiotics used to treat TB. MDR-TB is extremely difficult to treat; a full course of antibiotics can last up to two years, and trigger unpleasant side effects. Moreover, the drugs used are expensive, and are not always available. The goal of RespiriTB is to advance the development of new drug candidates that could be part of a new, more effective, shorter regimen to treat MDR-TB. The team is particularly interested in compounds that interfere with the TB bacterial energy metabolism. The project will carry out a range of studies on the drug candidates selected, including initial clinical studies in humans. Ultimately, the project hopes to contribute to the development of a new, more efficient combination drug regimen for MDR-TB, with a shorter treatment duration and a lower risk of further drug resistance.

RespiriTB is part of the IMI AMR Accelerator Programme.


  Show participants on map
EFPIA companies
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Medizinische Universitaet Wien, Vienna, Austria
  • Sorbonne Universite, Paris, France
  • Universiteit Antwerpen, Antwerp, Belgium
  • Universiteit Leiden, Leiden, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ffund BV, Amsterdam, Netherlands
  • Mitologics, Romainville, France

NameEU funding in €
Academisch Ziekenhuis Leiden1 074 533
Ffund BV211 036
Kobenhavns Universitet99 639
Medizinische Universitaet Wien840 189
Mitologics146 631
Sorbonne Universite343 875
Universiteit Antwerpen3 999 723
Universiteit Leiden124 375
Total Cost6 840 001